Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality

John P. Sheppard MD, MS , Leonard Palatnic DO , Suvasini Lakshmanan MD, MS , Thomas Drago MD , Jaspreet Bhogal MD , Sion K. Roy MD , Deepak L. Bhatt MD, MPH, MBA , Matthew J. Budoff MD , John R. Nelson MD
{"title":"Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality","authors":"John P. Sheppard MD, MS ,&nbsp;Leonard Palatnic DO ,&nbsp;Suvasini Lakshmanan MD, MS ,&nbsp;Thomas Drago MD ,&nbsp;Jaspreet Bhogal MD ,&nbsp;Sion K. Roy MD ,&nbsp;Deepak L. Bhatt MD, MPH, MBA ,&nbsp;Matthew J. Budoff MD ,&nbsp;John R. Nelson MD","doi":"10.1016/j.jacadv.2025.102149","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Purified eicosapentaenoic acid (EPA) and mixed eicosapentaenoic/docosahexaenoic acids (EPA/DHA) are omega-3 polyunsaturated fatty acids (n-3 PUFAs) of interest for preventing cardiovascular disease (CVD) as adjunct to statins. Randomized clinical trial (RCT) evidence continues to emerge, including data from the RESPECT-EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid) trial, but n-3 PUFAs’ roles in prevention remains controversial.</div></div><div><h3>Objectives</h3><div>The objective of the study was to assess the efficacy of EPA vs EPA/DHA compared to the standard preventive therapy across published RCTs investigating the use of n-3 PUFAs for primary or secondary prevention of CVD.</div></div><div><h3>Methods</h3><div>Following a prespecified protocol registered in the PROSPERO database (<span><span>CRD42023390587</span><svg><path></path></svg></span>), we identified RCTs reporting CVD-attributable mortality in patients randomized to EPA, EPA/DHA, or a standard preventive therapy for primary or secondary CVD prevention. We used random effects meta-analysis to estimate pooled HRs of CVD-attributable mortality achieved with EPA or EPA/DHA relative to the standard preventive therapy.</div></div><div><h3>Results</h3><div>Sixteen RCTs met the inclusion criteria, representing 127,771 patients in total (41% women, mean age 64 ± 5 years). Median follow-up was 3.7 years (IQR: 2.7-5.0 years). Compared to the standard preventive therapy, CVD-attributable mortality was significantly reduced with purified EPA (HR: 0.79 [95% CI: 0.67-0.94]; <em>P</em> = 0.006); this effect was less for EPA/DHA (HR: 0.92 [95% CI: 0.84-1.00]; <em>P</em> = 0.044).</div></div><div><h3>Conclusions</h3><div>EPA lowered incident CVD-attributable mortality in RCTs investigating its use for primary or secondary CVD prevention. Relative to EPA, benefits reported with EPA/DHA were attenuated. Although more work is needed to understand these differences, EPA should preferentially be used in cardiovascular conditions for which it is indicated.</div></div>","PeriodicalId":73527,"journal":{"name":"JACC advances","volume":"4 10","pages":"Article 102149"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772963X25005745","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Purified eicosapentaenoic acid (EPA) and mixed eicosapentaenoic/docosahexaenoic acids (EPA/DHA) are omega-3 polyunsaturated fatty acids (n-3 PUFAs) of interest for preventing cardiovascular disease (CVD) as adjunct to statins. Randomized clinical trial (RCT) evidence continues to emerge, including data from the RESPECT-EPA (Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid) trial, but n-3 PUFAs’ roles in prevention remains controversial.

Objectives

The objective of the study was to assess the efficacy of EPA vs EPA/DHA compared to the standard preventive therapy across published RCTs investigating the use of n-3 PUFAs for primary or secondary prevention of CVD.

Methods

Following a prespecified protocol registered in the PROSPERO database (CRD42023390587), we identified RCTs reporting CVD-attributable mortality in patients randomized to EPA, EPA/DHA, or a standard preventive therapy for primary or secondary CVD prevention. We used random effects meta-analysis to estimate pooled HRs of CVD-attributable mortality achieved with EPA or EPA/DHA relative to the standard preventive therapy.

Results

Sixteen RCTs met the inclusion criteria, representing 127,771 patients in total (41% women, mean age 64 ± 5 years). Median follow-up was 3.7 years (IQR: 2.7-5.0 years). Compared to the standard preventive therapy, CVD-attributable mortality was significantly reduced with purified EPA (HR: 0.79 [95% CI: 0.67-0.94]; P = 0.006); this effect was less for EPA/DHA (HR: 0.92 [95% CI: 0.84-1.00]; P = 0.044).

Conclusions

EPA lowered incident CVD-attributable mortality in RCTs investigating its use for primary or secondary CVD prevention. Relative to EPA, benefits reported with EPA/DHA were attenuated. Although more work is needed to understand these differences, EPA should preferentially be used in cardiovascular conditions for which it is indicated.
二十碳五烯酸与二十碳五烯酸/二十二碳六烯酸对心血管死亡率的影响
纯化二十碳五烯酸(EPA)和混合二十碳六烯酸/二十二碳六烯酸(EPA/DHA)是omega-3多不饱和脂肪酸(n-3 PUFAs),作为他汀类药物的辅助药物,可用于预防心血管疾病(CVD)。随机临床试验(RCT)证据不断出现,包括来自RESPECT-EPA(评价他汀类药物和二十碳五烯酸联合治疗的二级预防疗效的随机试验)试验的数据,但n-3 PUFAs在预防中的作用仍然存在争议。本研究的目的是评估EPA与EPA/DHA相比标准预防治疗的有效性,这些已发表的随机对照试验调查了n-3 PUFAs用于心血管疾病一级或二级预防的情况。方法:根据在PROSPERO数据库(CRD42023390587)中注册的预先指定的方案,我们确定了随机分配到EPA、EPA/DHA或标准预防治疗的原发性或继发性CVD预防的患者中报告CVD归因于死亡率的rct。我们使用随机效应荟萃分析来估计EPA或EPA/DHA相对于标准预防治疗所达到的cvd归因死亡率的总hr。结果16项rct符合纳入标准,共纳入127771例患者(女性41%,平均年龄64±5岁)。中位随访3.7年(IQR: 2.7-5.0年)。与标准预防治疗相比,纯化EPA可显著降低cvd归因死亡率(HR: 0.79 [95% CI: 0.67-0.94]; P = 0.006);EPA/DHA的影响较小(HR: 0.92 [95% CI: 0.84-1.00]; P = 0.044)。结论:在调查sepa用于一级或二级CVD预防的随机对照试验中,sepa降低了CVD可归因死亡率。与EPA相比,EPA/DHA的益处有所减弱。尽管需要更多的工作来了解这些差异,EPA应该优先用于心血管疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JACC advances
JACC advances Cardiology and Cardiovascular Medicine
CiteScore
1.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信